Biogen Inc. (BIIB) Earnings Call Transcript & Summary

October 30, 2024

NASDAQ US Health Care Biotechnology earnings 63 min

Earnings Call Speaker Segments

Steve Amato

executive
#1

You can find details in the filings we make with the SEC, and I'd urge you to take a look at those. Materials including our earnings release and other papers about our results, plus the reconciliations comparing GAAP and non-GAAP figures talked about on this call, are available in the Investors portion of biogen.com; the slides we'll use today have also been placed on our website. Joining me for this call are our President and Chief Executive Officer, Chris Viehbacher, Dr. Priya Singhal, Head of Development, Mike McDonnell, Chief Financial Officer, and our Head and President of North America, Alisha Alaimo, who will be around for Q&A. After some opening remarks, we'll go to the Q&A session. So that we can work through as many questions as we can, we ask that you please keep to one question. I'll now hand the call over to Chris.

Chris Viehbacher

executive
#2

Thank you, Steve. Good morning, everyone. To begin, I'd like to say how grateful I am to you, Steve, for stepping into the Interim Head of IR position and for the excellent work you've done preparing us for this quarter. In addition, we announced earlier this week that our CFO, Mike McDonnell, intends to retire, and that Robin Kramer will take over the role. Even so, Mike is still fully in place as CFO, and we will celebrate everything he has given to Biogen during the fourth quarter earnings call later on. In my view, Biogen has made remarkable and quite robust strides across the past two years, and I truly believe the company is positioned well for what lies ahead. Things are moving along nicely with our launches, showing solid growth from one quarter to the next. We've brought our cost base down a lot, but what matters more is that a value-for-money mindset around spending has really taken hold in our culture. The acquisitions we've completed so far have gotten a positive reception and are already generating value, and I believe a strong late-stage pipeline is taking shape. So let's begin with the launches and talk about Leqembi first. Now, while it's true that Leqembi revenue in the U.S. Even so, results remain under what our partnership had hoped for, and the number of prescribing doctors hasn't widened as much as we expected. Yet worldwide sales rose 66% during Q3 versus Q2, with ongoing adoption abroad and roughly 40% more prescribers added in the United States. Our alliance keeps honing its go-to-market approach, and gains are showing up thanks to a bigger sales team — those reps actually began working in the field on September 1st — while we keep assessing ways that might speed up the business. To start, we keep observing certain American healthcare systems broadening their footprint and adding new locations for treatment. More lately, sizable infusion networks have begun coming online in densely populated regions to help manage the volume of patients seeking care. Outside America, we're pleased with how quickly adoption has grown—Japan being a clear example, where revenue was almost twice what it had been in the prior quarter. The launch efforts have been outstanding, especially in Japan and China, and it appears a single-payer setup has supported that type of expansion as well. Taking everything together, for Leqembi we anticipate sequential gains from one quarter to the next in the near term. We think several possible future events could speed up adoption. These include IV maintenance possibly becoming available as early as next year, a subcutaneous version for maintenance and later for induction, and broader use of blood-based diagnostics. To show just how significant a relief this is for doctors, a few of you might have seen an opinion piece published in JAMA Neurology on October 14th, authored by Katherine Possin from UCSF, Jeff Burns from University of Kansas, and Brent Forester from Tufts. They mention this being a period of unmatched progress, yet in the same breath they state, "The difficulty and significance of moving scientific breakthroughs in diagnostics, treatment, and care into practice promptly and fairly cannot be overstated. To fairly bring advances to scale, innovation is required at the clinic, healthcare system, and policy levels." So our view remains that this will be a significant market, but once more, we don't see ourselves as facing a demand problem. The healthcare system simply needs time to adjust to caring for this many patients. Moving on to Skyclarys, as our footprint widened, especially across Europe, we experienced greater demand worldwide. Revenue for Skyclarys is now coming in from both commercial and other paid mechanisms across 15 markets outside the U.S. That covers several EU nations where demand keeps climbing quarter-over-quarter. At this stage, I want to note that revenue generation in the U.S. differs from how demand is developing in Europe; stateside, our revenue grows in step with the rate at which we identify patients. In Europe, we're already commercializing the product on the ground, and we have several early access programs running, yet for many products in Europe the approach is to enroll patients while negotiating with governments over reimbursement; eventually those governments then reimburse those patients, and you suddenly have a population of patients already on treatment and ready to go. So as you examine the quarter-on-quarter progression, the ex-U.S. portion won't mirror rising demand — instead it will mirror the timing of when we secure reimbursement from governments. Still, I can tell you that in Europe we're adding patients daily and weekly at a pace beyond what we expected. We're now aiming to broaden access to more patients, and 11 regulatory filings have been submitted around the world so far; so our focus is now beyond the U.S. and Europe, and those could begin producing revenue as early as next year. Commercially, Zurzuvae keeps surpassing our expectations in the U.S., where third-quarter revenue reached $22 million, which is a 49% rise versus the second quarter, helped along in part by a 40% gain in patients this quarter. In my view, the team has performed exceptionally on this launch; across all the cases we've discussed — Leqembi, Skyclarys, and Zurzuvae — let me remind everyone that none of these are pre-existing markets; in every instance we are building the market, and that invariably takes longer than incremental innovation, where you enter and simply aim to capture some share from a market that already exists. So, Steve, could we change the slide. What we're aiming for is growth that can be maintained, and that applies both near term and over the medium term. Upon joining this organization, I set out really 3 main goals. The first was getting Biogen back to a revenue trajectory that can be sustained, the second was creating a pipeline capable of supporting that growth for Biogen far into the 2030s, and the third was developing a group of leaders who will propel this company toward even greater success during the 2030s; so when we examine the pipeline, I must say, what we're seeing take shape makes us quite enthusiastic. To repeat, we are Biogen; incremental innovation isn't what we pursue, yet I believe there are several genuinely compelling products we feel really good about because, in contrast to many past Biogen products, where we enter phase III without truly knowing if they'll succeed, we've observed a great deal in biomarkers, in data, and other indications pointing to a; our confidence in these assets keeps building. With BIIB080, what stands out to me is that even though it's an intrathecal, as Priya will tell you, we enrolled patients quickly on this one, and enrollment is now complete. For me, having spent more than 35 years with commercial experience, watching a clinical trial fill its enrollment quickly, especially in a crowded field where therapies already exist, bodes well for that product later on. On dapirolizumab, positive phase III results came through, and I want to congratulate Priya, since Priya had already given this thought and collaborated with UCB, and a phase III protocol is in fact ready, so we'll be launching phase III shortly. Lupus represents an enormous area of unmet need, and we have not just dapi, but litifilimab across two indications, and beyond those, felzartamab as well, in lupus nephritis. Regarding felzartamab, we obtained some highly encouraging data in San Diego and IgAN, and breakthrough status has been granted on AMR; for our pipeline this changes the game, because once again, here we possess phase II data that appear extremely compelling. Everyone recognizes there are no certainties when developing a pipeline, yet at minimum we have, I believe, grounds to think these products might reach the market and deliver a significant impact. And when we begin examining peak revenue for every one of these products, the total across all of them, assuming each one actually reached the market and received approval, comes to roughly $14 billion in cumulative peak sales. And given that our pharma business currently sits at approximately $7.5 billion, this late-stage pipeline has the potential to genuinely reshape Biogen over the longer term. That said, I probably shouldn't be the one discussing pipeline. The true authority here is Priya, so with that, I'll hand things over to Dr. Singhal.

Priya Singhal

executive
#3

Thank you, Chris. As Chris pointed out, our attention over these past 24 months has been squarely on strengthening the pipeline, aiming to turn innovation into medicines that are both novel and impactful. Because of that effort, I think the pipeline we hold today contains multiple programs backed by encouraging clinical data while also carrying the potential to bring real value to patients. That group includes dapi in SLE, litifilimab for both SLE and CLE, felzartamab across several immune-mediated diseases, plus our tau ASO BIIB080 in Alzheimer's, as Chris mentioned. Making progress on these programs stays our number one priority, yet we are simultaneously pursuing acceleration strategies throughout the wider portfolio so decisions get made faster, all while keeping execution front of mind. BIIB080 stands out as a key illustration: we finished enrolling under the amended phase II design not long ago and now anticipate a readout during 2026. On top of that, given the positive phase III data reported last month, we are acting with real speed alongside our collaboration partner UCB to launch a second phase III trial of dapi in SLE before this year ends. We are additionally putting new and creative clinical development approaches in place to strengthen clinical execution and shorten cycle times. That covers efforts such as deploying AI to assist with optimizing which sites get selected and how trial participation is handled. Alongside all of this, and consistent with our goal of steadily growing the pipeline, we are collaborating with research and corporate development teams to assess outside innovation opportunities spanning the development stage and a number of indications. Taking it all together, we feel these objectives give us the chance to act on the substantial opportunity Chris has described for Biogen. Now, on the quarter, I want to start with Alzheimer's, where our work with Eisai continues to produce valuable insights regarding Leqembi in early AD. That spans things such as long-term treatment effect and real-world evidence, like what was shared at CTAD, but just as importantly, we are striving to give patients optionality. With data showing expanded benefit from ongoing Leqembi treatment that goes past simply clearing plaques, we keep pursuing maintenance dosing choices; decisions from regulators on maintenance dosing for the IV as well as the subcutaneous autoinjector are anticipated next year, in 2025. Beyond that, the AHEAD 3 to 45 study, which assesses whether Leqembi can prevent or delay Alzheimer's in preclinical or pre-symptomatic AD, saw strong enrollment, and enrollment was just finished this month, in October. I'm eager for us to share updates as this trial moves forward. We are likewise seeking to broaden our leadership position by pushing forward novel treatment approaches, among them shuttles targeting various disease states and targets, as seen with BIIB080. Shifting to immunology, we think we are assembling a late-stage pipeline that leads the industry, made up of programs with proven proof of concept. These programs span a variety of immune-mediated diseases marked by considerable unmet need. That covers the felzartamab acquisition we made not long ago. For that asset, our plan is to kick off three phase III trials in the coming year — in AMR, IgAN, and PMN — and at the same time keep exploring additional indications where this mechanism of action might prove useful. On top of that, we have several programs underway in SLE. It's estimated that more than 3 million people around the globe live with this condition, and the therapies used today tend to deliver suboptimal efficacy along with a range of treatment-related toxicities, which produce lasting negative consequences like organ damage. In the U.S., SLE ranks as the leading cause of death among women between 15 and 24 years old, and options for treating patients before, during, and after pregnancy remain limited, given safety concerns and contraindications that apply to most common therapies. To highlight what our immunology pipeline can offer, we're happy to share that the phase III trial of dapi plus standard of care hit its primary endpoint, demonstrating a statistically significant greater improvement in disease activity as measured by the BICLA endpoint at 48 weeks compared with placebo plus standard of care. Equally important, we observed clinical improvements across key secondary endpoints that assess disease activity and flare prevention — two areas that stand out as key treatment goals when managing SLE. After the earlier phase II trial, Biogen and our collaboration partner, UCB, took time to analyze the results, aiming to design a phase III study and de-risk it while demonstrating a potential treatment effect. Those learnings, along with what we understand about the underlying disease biology, shaped how the phase III study was designed, including updated screening criteria so that patients enrolled had active disease requiring a biologic therapy on top of standard of care. This approach's success stands out given that, across the past 20 years, dapi is only the third molecule to deliver positive phase III results in a global SLE study. We're eager to present detailed results from this phase III study as a late breaker at next month's ACR annual meeting, and alongside UCB, we expect to launch the second phase III study within this year. Now shifting to SMA, our focus has consistently been on finding ways to keep improving patient outcomes. Earlier this month, at the World Muscle Society meeting, we were glad to present detailed results from the DEVOTE study, which evaluates the investigational higher dose regimen of nusinersen. That higher dose regimen is made up of two 50 mg loading doses, followed by 28 mg maintenance doses administered every four months. With this high dose regimen, the amount of drug delivered in the first administration exceeds what the full two-month loading phase of the approved Spinraza 12 mg regimen provides. Matching the faster loading approach, higher dose nusinersen slowed neurodegeneration more quickly than Spinraza 12 mg, based on neurofilament measured at day 64, an objective biomarker. In part B of DEVOTE, the pivotal infantile onset cohort achieved the primary endpoint of change from baseline to six months in the CHOP INTEND relative to the pre-specified matched sham group, showing a clinically and statistically significant improvement. We also saw patterns indicating a lower chance of death or needing permanent ventilation, compared with both the sham control group and the regimen that is approved today. In addition, we presented early findings from the open label part C section of the trial, involving participants between the ages of four and 65 who moved over from Spinraza 12 mg following roughly four years of treatment on average. After switching to a higher dose, this group demonstrated gains in motor function. These results are thrilling, given our efforts to assist patients who are currently receiving disease-modifying therapies. It's important to note that the high-dose regimen was generally well tolerated, with a safety profile resembling that of the approved 12 mg regimen. We think these findings underscore the distinctive promise of Spinraza in helping to tackle the unmet needs that remain for people living with SMA, and we intend to file for global regulatory approval later in the year. To wrap up, over the last quarter, I feel we kept executing effectively and hit a number of key development milestones that demonstrate how our pipeline could bring meaningful new treatments to patients. Beyond the late-stage data readouts in lupus and SMA, we filed in the U.S. for zuranolone and PPD, and secured approvals for Skyclarys and Qalsody in Switzerland and China, respectively. We additionally shared fresh data insights spanning several disease areas at various medical conferences, covering Alzheimer's, neuromuscular, and renal disease. As of today, we think the pipeline is nicely set up to produce a steady rhythm of pivotal readouts and possible launches. We remain committed to striving to deliver transformative medicines into patients' lives, while fulfilling Biogen's goal of sustainable growth. Moreover, I think the very same foundational strengths and deep therapeutic area knowledge that let us revamp our existing pipeline and build leading positions in fields such as Alzheimer's, immunology, and rare disease also give us a unique edge in assessing outside innovation as we pursue ways to strengthen our pipeline. Having said that, I'd like to turn the call over now to Mike for an update on finances.

Mike McDonnell

executive
#4

Thanks, Priya, and good morning, everybody. I want to give you some context around what we saw in Q3, and whenever I make a comparison, it's against Q3 of 2023 unless I say something different. Revenue on a total basis came in at $2.5 billion. That total figure and our core pharmaceutical revenue each fell 3%. Non-GAAP diluted EPS landed at $4.08, which represents a 6% decline. Shortly, I'll walk through a few more specifics on some important dynamics worth flagging from Q3. Non-GAAP operating income rose 4% compared with Q3 of 2023, as we keep realizing gains from our R&D prioritization and Fit for Growth initiatives. We're happy to be lifting our full-year 2024 guidance range once again, and in a few moments I'll share some further context on that increased guidance range for 2024. A handful of remarks about Q3 revenue. Revenue from our MS products dropped roughly 9%, mainly due to competitive dynamics within the space, plus certain channel dynamics. Significantly, we shared last week that the European Patent Office confirmed the validity of Biogen's Tecfidera-related patent covering DMF dosing, which runs out in February of 2028. We're happy about that ruling. That said, generics are contesting this patent, and we do expect additional challenges. Tysabri has felt effects from a biosimilar entrant in Europe, and while no biosimilar has launched in the U.S. yet, we keep seeing intensifying competition within the high-efficacy class. Turning next to our rare disease franchise, which generated $495 million in revenue, representing 10% growth. The Skyclarys launch keeps advancing in the U.S., where $82 million in revenue was up 8% versus the second quarter, powered by greater demand. Skyclarys is now producing revenue across 15 countries outside the U.S., with global revenue of $102 million in Q3. That rose slightly from the second quarter, fueled by higher demand, and was partly offset by certain pricing and reimbursement dynamics in a few newly launched markets. Global Spinraza revenue of $381 million was down $67 million, or 15%, and took a hit from losing an annual tender in Russia, which created an unfavorable impact of roughly $45 million during Q3. It's worth highlighting that this tender, which happens and adds to revenue only one time per year, weighed on Q3 2024 results, but we don't anticipate any further revenue effect for the remainder of this year. The global decline was also affected by shipment timing and certain foreign currency. Spinraza U.S. revenue grew 2% to $153 million, and we stay encouraged by how it's performing here. Zurzuvae brought in $22 million of revenue this quarter, which is up 49% from the second quarter, and we remain encouraged by rising demand. Once more, Leqembi posted sequential growth. Eisai recorded roughly $67 million in worldwide in-market sales for the third quarter, which represents a 66% rise compared with the second quarter. U.S. in-market sales for Leqembi came to $39 million. That marks a 33% increase over the second quarter. And lastly, revenue from contract manufacturing, royalties, and other sources totaled $250 million. As anticipated, that figure was considerably lower than a year earlier, owing to the wrapping up of specific batch commitments during 2023. I'll now offer some remarks regarding third-quarter expenses. Non-GAAP cost of sales, measured as a share of revenue, fell two percentage points, mainly because of product mix — in particular, the year-over-year revenue gain from new product launches alongside the drop in contract manufacturing revenue, plus reduced idle capacity charges. Non-GAAP R&D expense came down by $48 million, reflecting the ongoing advantages of our R&D prioritization initiatives. Non-GAAP SG&A expense rose 1% during the third quarter, since gains from our Fit for Growth initiative let us absorb the bulk of the $45 million in additional third-quarter costs tied to our launches. Our belief remains that we can secure $1 billion in gross savings and $800 million in net savings through our Fit for Growth initiative by the close of 2025. Non-GAAP EPS for the third quarter stood at $4.08. Certain non-operating items weighed unfavorably on EPS, among them a roughly $80 million reduction in net interest income stemming from lower cash balances following the Reata and HI-Bio acquisitions; partially counterbalancing that were some favorable tax items during the quarter, which contributed about $16 million to our net income. Now, a quick update on our balance sheet. We closed the quarter holding $1.7 billion in cash and marketable securities, along with roughly $4.6 billion in net debt. We managed to produce about $901 million in free cash flow, marking our strongest free cash flow since the second quarter of 2021. Free cash flow in the third quarter of 2024 gained partly from some favorable working capital dynamics. It remains our view that our balance sheet is strong and gives us the capacity to keep investing in both internal and external growth opportunities. Moving on to guidance, we're pleased that business performance so far this year once again supports lifting our full-year 2024 non-GAAP diluted EPS guidance range from between $15.75 and $16.25 to a new range of between $16.10 and $16.60. At the midpoint of this new range, that reflects expected growth of approximately 11% relative to full-year 2023. Let me call out a few key assumptions underlying this guidance. First, on the top line, our expectation remains that total revenue will fall by a low single-digit percentage. And as we've said all year, we expect to keep ramping investment behind our new product launches and key R&D programs, which includes felzartamab following our acquisition of HI-Bio. And finally, like what usually happens in our business, we anticipate SG&A spending will be seasonally greater during the fourth quarter than it is across the remainder of the year. I'd point you toward this slide, along with our press release, for additional significant guidance assumptions; to wrap up, our attention stays on pushing forward the product launches currently underway and the critical portions of our late-stage pipeline; we think our work in those areas will assist in placing Biogen for sustainable growth over the long term, which remains our top objective. And having said that, we'll now take questions on the call.

Brian Abrahams

analyst
#5

Hi there, good morning, and thank you very much for fielding my question. What I'd like to know regarding Leqembi is when you anticipate greater pull-through from the broadened commercial push, and whether any of those signs are beginning to show up in October; you also referenced in your prepared remarks the possibility of additional commercial acceleration strategies. Could you elaborate on that a bit further and describe how well aligned you are with Eisai regarding the commercial plans? Thanks.

Chris Viehbacher

executive
#6

Sure, Brian, I'll handle the second portion of your question and then hand things to Alisha, who can provide a bit more detail on the enlarged field force. As you know, we've picked up a tremendous amount, truly, over the years since this product was introduced. The launch itself truly got underway in the fall of last year. We had to have the entire commercial organization assembled, yet we also required clarity on matters such as reimbursement for PET scans; therefore, for us, I view this as essentially the one-year mark of the launch, and many things are now becoming clear to us: how long it may take for IDNs to truly establish their protocols and care pathways, plus there are various other elements such as determining the appropriate patient, and we also have considerably more data arriving. The subcutaneous formulation should come, we hope, next year, for maintenance, and the IV for maintenance at some point next year, so it feels like the right moment for both partners to join together and simply assess what is going well and what more we could do, so we'll likely be in a position to share additional detail on that. I'd say the teams collaborate very effectively. Both of us recognize that this launch is highly complex, I'd argue more complex than most that I've personally witnessed, and I believe most others have witnessed as well, and even so we do observe plenty of physicians, once again, who are investing a great deal of effort to make all of this work, to sort through patients and determine who truly is the appropriate candidate. A large proportion of patients who come to the neurologist cannot receive treatment, then there's the coordination of PET scans or lumbar punctures, the MRIs, and the infusion beds; we've witnessed a great deal of genuine effort across the marketplace, and we add prescribers each week, and we record more sales each week. I believe that's how progress will unfold, likely right up until we have the subcutaneous for induction. In my view, that may prove to be quite a game changer. Also, greater reliance on blood-based diagnostics rather than the PET scan. Both of those, I believe, would substantially lessen the burden on physicians. Alisha, perhaps you could discuss the enlarged field force and anything else you feel would be useful.

Alisha Alaimo

executive
#7

Yes. Thanks, Chris, and thanks for asking that, Brian. In Q3, as everyone has observed, our launch made consistent headway, much like we saw in earlier quarters, and that includes the figure for new patients. Another positive signal, one that isn't visible in the trends available to you but is visible to us, is the count of total prescribers writing. In fact, during Q3, the number of new writers rose 40% compared with Q2. So you're watching these doctors join week after week, with IDNs also broadening week after week. Still, when everything is said and done, exactly as was true at the launch's start and remains true today, jumping ahead to now that we've spent time in the field, what market research identifies as the primary obstacle continues to be those infrastructure difficulties, which Chris mentioned. That said, with the new Biogen team now in place, we can also verify that this ranks among the top worries particularly for physicians who have not yet written. Their next worry, naturally, remains ARIA, though it looms less large than it once did. Still, after they get some patients through the process and settle on their protocols, you can observe that easing. That said, our entire field force is now deployed, and keep in mind, we were extremely deliberate as a company about whom to bring aboard. We enjoyed somewhat of a fortunate position back when these roles were posted: more than 1,000 people applied, while the number of positions we had posted was only slightly above 25. That let us genuinely handpick people who either brought a background in Alzheimer's disease or a background in these territories, with existing relationships already in place. So at this point the teams have spent multiple weeks in the field. We're beginning to notice, within the specific offices where Biogen has overlaid with Eisai, that where we're engaging, growth appears somewhat more rapid than what's occurring across the remainder of the country. We can connect with a greater number of targets. Beyond that, doors open somewhat more readily for us since, once again, those reps already had relationships with physicians from before. Looking further out, we're clearly going to keep pursuing frequency and depth. Yet when all is said and done, take the Pacific Northwest, for instance: we had a rep whose relationship actually dated back 17 years, from prior work in MS. That person could assist a physician immediately. A different physician in the Southeast had a relationship spanning more than 20 years. They managed to unlock over 30 patients, I believe, within a span shorter than two weeks. So the relationships, we've found, have counted for something. The history has counted too, and some acceleration is beginning to appear, even though the teams have been fully in the field for only roughly a month.

Steve Amato

executive
#8

Thanks, Alisha. Let's take the next question.

Phil Nadeau

analyst
#9

Good morning. Appreciate you taking our question. Chris, you've mentioned the subcutaneous formulation a few times already today. Could you provide us with a little more of an update regarding where things stand with the subQ filings, for maintenance and for induction as well? Thanks.

Chris Viehbacher

executive
#10

Certainly. I'll hand that to Priya.

Priya Singhal

executive
#11

Absolutely, Phil — thanks for raising that. We're still focused on getting our subcutaneous maintenance filing fully finished, just as Eisai has said, and we anticipate that happening very soon. After that, we move to initiation, where we're working to produce the data and run the analysis; this falls under the subcutaneous substudy within the CLARITY Open-Label Extension study. And per what Eisai has communicated, we're still on schedule to see a regulatory decision regarding subcutaneous initiation therapy in Q1 of calendar year 2026.

Steve Amato

executive
#12

Thank you, Priya. Next question, please, operator.

Marc Goodman

analyst
#13

Yes. Might you expand a bit further regarding Skyclarys outside the US? During the opening remarks, something was said concerning pricing and reimbursement dynamics. If you could provide a bit more detail on those difficulties, that would be helpful. Thank you.

Chris Viehbacher

executive
#14

Yeah. So, as is known, once you secure approval across Europe, the next step involves going nation by nation to work out reimbursement terms; and essentially, what we've already begun is meeting with doctors, and patients are being placed on therapy. However, how much revenue those patients actually produce differs from one country to another; so in certain nations, for example, charging for an early access program is possible. In others, it isn't. Certain nations allow you to obtain reimbursement significantly sooner than other European nations do; so that process is underway for us. What we haven't yet done is truly kick off the revenue generation, pardon me, the patient demand generation alongside reimbursement. We're engaged across every country and enrolling patients. Consequently, we're monitoring patient counts, which are rising substantially month over month. What will become visible in the quarterly revenue figures is the point at which those patients turn into revenue-generating patients; and by nature, that's going to be somewhat uneven, since patient demand actually runs ahead of when revenue gets generated. And for those programs offering early access that can be paid for, a price has to be set. Yet in certain instances, a clawback applies should the reimbursed price end up below the price you're charging. And clearly, as we enter countries and gain a clearer sense of where the price point sits, we've needed to make certain adjustments to revenue we had booked under those programs where charging for an EAP is permitted. That's simply a standard part of most European launches.

Steve Amato

executive
#15

Thanks, Chris. Operator, let's take the next question.

Salveen Richter

analyst
#16

Good morning, and thank you. Chris, you discussed what's being done regarding the late-stage pipeline and R&D, yet you also mentioned the business development lever. Do you have any fresh perspective on what the strategy will be going forward for that latter piece?

Chris Viehbacher

executive
#17

Yeah. Essentially, our industry finds itself in a familiar bind: we've got an older set of assets dealing with tougher competition, while ahead of us sits a highly promising pipeline — so how do you get from one side to the other? Some businesses decide to just ride it out and hold on until that pipeline shows up. Between now and 2028, our business will probably grow. Still, I'd characterize that growth as not really satisfying to us. That's why we keep searching and will keep searching. Personally, I devote a substantial amount of my time to this. Could there be assets we bring aboard that boost near-term revenue growth while still generating value for shareholders? Simply purchasing revenue doesn't interest us much. If growth can be acquired and a strong return on investment achieved, we'll go ahead. However, as you're aware, prices climb steeply once assets near the market. That means an enormous amount of digging and examining is required, which is exactly what we're doing. We've got an entire team reviewing both public and private companies. Considerable financial capacity remains at our disposal, I believe. Mike might want to weigh in on that; we're active on this front, yet we remain disciplined fiduciaries of shareholder money. My long-standing view is that we're paid to enrich our shareholders, not someone else's.

Mike McDonnell

executive
#18

Okay, Salveen, regarding capacity, to provide some context, we closed out the quarter holding roughly $1.7 billion in cash. Considering our capital structure, total debt stands at approximately $6.3 billion, against an EBITDA run rate of around $3.3 billion to $3.4 billion. So gross leverage sits under two times, which is quite a conservative level. On the capacity front, we're happy with roughly $2 billion in free cash flow so far this year, including $901 million during the quarter. With a few billion dollars or more in annual free cash flow and gross leverage below two turns, it's clear that across the coming couple of years, assuming you layer in a sensible level of additional debt at some stage, alongside that free cash flow and the cash we already hold, you have comfortably $8 billion to $10 billion in available capacity over the next year or two for partnering, doing deals, evaluating acquisitions, and pursuing other opportunities to bolster our growth.

Steve Amato

executive
#19

Thank you, Mike. Next question, please, operator.

Michael Yee

analyst
#20

Thanks. Morning, everyone. So we saw that enrollment for AHEAD 3 to 45 has wrapped up, and I'd like to ask Priya whether she could walk us through what the expected timeline looks like, and beyond that, whether there might be room for an interim analysis, and if so, what that would rest on. From what I gather, these patients are quite early in the presymptomatic phase. Is there any enrichment happening in that population, and what makes you think this could read out positively? Thank you.

Priya Singhal

executive
#21

Thanks, Michael. Yes, we're pleased that AHEAD 3 to 45 finished enrolling in October. As a reminder to everybody, this is 2 trials — one focuses on early intermediate amyloid stages, so patients at those early intermediate stages, while the other involves a heavier amyloid burden. These are quite sizable studies. Roughly 400 patients are in AHEAD 3, the earliest intermediate stage, and around 1,000 patients are in AHEAD 45. On timing, there's a 216-week time point in these trials. That said, we're simultaneously working with regulators and reviewing every possibility for when results might be ready. We'll keep sharing further updates, but completing enrollment has us really enthusiastic, particularly since data we've presented from the CLARITY study demonstrates that when you treat early, in patients with low tau or none at all, you observe substantial benefits when it comes to stabilization and even actual clinical improvement. So this remains a truly thrilling area for patients to have treatment options, which is why we're so enthusiastic about where things stand right now.

Steve Amato

executive
#22

Thanks, Priya. Can we take the next one?

Umer Raffat

analyst
#23

Hey, everyone. I appreciate you taking my question. I figured I'd switch gears for just a moment and touch on something a bit different. It certainly appears that a substantial level of R&D spending is flowing into lupus — across dapirolizumab, your BDCA2 molecule, and potentially the CD38 one too. My larger question, I suppose, is this: you've reached a phase III, which is clearly encouraging, yet at the same time we're witnessing remarkable remission results from certain CD19 CAR-Ts, and that could perhaps even show up in some CD19 bispecifics too. So it looks as though you don't have much presence in that particular space — CD19 bispecifics. So how should we think about weighing things, by the time you ultimately reach this market, against some of the emerging data from possible CD19 bispecifics or the T-cell engagers? Thanks so much.

Priya Singhal

executive
#24

Thanks, Umer. Yes, we keep monitoring innovation in this area, and for patients it's thrilling. But I think if you take a step back and consider what potential dapi might deliver, along with the data we've shared — and we'll share additional data at ACR in a few weeks, and it is embargoed — what we've observed in this moderate to severe population has us very excited. So stepping back, when you consider SLE, it truly is a chronic disease, quite heterogeneous, with a heavy global burden of disease, particularly among women and underserved populations. And we think many options are going to be needed. So while the bispecifics and the CAR-Ts might demonstrate efficacy in small populations, we must remember that these are very small data sets and likely might not apply to the whole population. I think this is where the scientific hypothesis and continuing to generate data in phase II — which leads us to believe we could have a high probability of success in phase III — becomes truly important. With dapi, we're actually targeting and inhibiting the CD40 ligand, which can reduce B-cell activation and downregulate interferon pathways. Then, with litifilimab, we're pursuing the type I interferon signature and really focusing on inhibiting BDCA2 in the plasmacytoid dendritic cells. We think this will be truly important, and probably many options are needed, but we stay very optimistic about the data we've seen thus far and the momentum our trials have. We remain believers in these pathways and programs. With litifilimab, as you're aware, we're also tackling cutaneous lupus, where truly there's been no innovation for 70 years. So again, we have strong scientific conviction, as Chris mentioned, and we'll keep prosecuting these.

Chris Viehbacher

executive
#25

I'd like to chime in here, Umer. More than 15 years back, while I was employed at GSK, we had Benlysta in development, and due to its modest efficacy, we came very close to shutting that program down — that is, until it became clear that all the other candidates were failing and ours was the only one left. As of today, just 2 products have received approval. Dapi would make 3. And I can share that across those years, we've observed a tremendous amount of data from small populations, exactly as Priya mentioned. Consequently, I believe we must hold off and watch which one truly crosses the finish line. Regarding CAR-T, yes, there's some compelling data, but in my own view, the logistics surrounding CAR-T aren't at a point yet where you'll observe meaningful quantities of patients receiving treatment; therefore, like Priya noted, an unmet need exists right now; we possess a product showing proven results; we're proceeding at full speed. And considering how this disease behaves, I suspect you'll discover that no single product will end up being the victor. A variety of approaches will be required.

Steve Amato

executive
#26

Thank you, Chris. Next question, please, operator.

Jay Olson

analyst
#27

Oh, hi there, congratulations on the quarter, and thanks for fielding my question. We're interested in that $14 billion figure for peak revenue potential across your four main pipeline programs. Could you discuss how much each of the four products might contribute and when they'd arrive, in terms of which are biggest and closest in time? Thanks.

Chris Viehbacher

executive
#28

Giving specific revenue projections for each one isn't something I want to do. The intent, I think, was to convey the scale of what's in the pipeline. Obviously, none of us can count on every single thing working out. Still, I'd say if you consider where the meaningful programs will be — take BIIB080 in Alzheimer's — our belief is strong, and Biogen isn't alone in that. Lilly and Roche, as I see it, keep putting substantial money in. You've watched AbbVie commit quite a huge sum for a very early-stage Alzheimer's asset. So the shared view, I think, is that once the healthcare system can finally adjust to the enormous demand for treatment, this turns into a major market. And from what we can observe — I visited a top-tier medical school just last week, spent a day among many Alzheimer's researchers there — their enthusiasm for tau is unlike what we've typically seen with amyloid-beta. How severe Alzheimer's gets really tracks with tau levels, and many people in this field genuinely hold the belief that targeting tau will deliver a meaningful patient benefit. So BIIB080, we do consider a product with enormous potential; and as Priya mentioned, we have dapi, plus litifilimab, and felzartamab in lupus nephritis too; so lupus, in our view, will be a substantial market. And then again, consider Benlysta, selling roughly $3 billion annually, and there's an AstraZeneca product that hasn't performed as strongly. But when you consider patient counts, this market still has plenty of room to grow; and with felzartamab, we have three phase III programs underway, and we view all three indications as major opportunities. So once more, add it all together. $14 billion is sort of the ceiling figure, but our teams' estimate falls somewhere between $9 billion and $14 billion. Of course, we must wait and see how the clinical trial data turns out and what the actual profile is. But considering these markets' potential, the unmet need, and the chance for differentiation, our excitement about this emerging pipeline keeps growing.

Steve Amato

executive
#29

Thanks, Chris. Let's take the next question.

Evan Seigerman

analyst
#30

Hey, everyone. We really appreciate you taking my question. In the past, as I recall, we discussed the possibility that Spinraza could get back to growing. With this quarter's numbers coming in softer, could you explain how you expect that to happen? Does it depend on high-dose nusinersen, or are there additional factors and levers available to speed this product's growth back up? Thank you.

Chris Viehbacher

executive
#31

On a global basis, in fact, when we set aside certain one-time effects, or what you might call the exceptional effects, from markets outside the U.S. and outside Europe, we actually did observe growth for Spinraza. This is obviously a highly competitive market; it turns out that despite having an intrathecal administration, what truly counts in very severe diseases is efficacy. That's the basis on which we compete. We had a study demonstrating, for instance, the benefit of adding Spinraza onto Zolgensma as gene therapy; we're aware that oral therapies come with limitations regarding which patients are able to be treated. Our teams, I believe, consider DEVOTE to be hugely important, because we're able to get through the loading doses and reach the appropriate level of therapeutic benefit more quickly than was possible before. That in fact cuts down on the number of intrathecal injections, at least during the loading phase; so I'd say this is genuinely an efficacy gain. But I'll turn to Alisha, at least from the U.S. angle, for how you view that.

Alisha Alaimo

executive
#32

Hey, thanks Chris. And hi, Evan. Appreciate the question. Spinraza has truly been a major driver, particularly within the U.S. market; and in rare disease, we feel Spinraza genuinely established that standard for what outstanding efficacy looks like and how it carries through to a patient. So growth compared to the prior year, which my team has witnessed, and that's even while facing two very formidable competitors; we launched an oral option while stay-at-home orders were in place, and the team continues to truly lead with Spinraza. We think there are a few reasons for that. First, the product's efficacy is clearly very strong, and a significant portion of our growth also comes from switchbacks. Many patients are coming back to Spinraza after having switched to a competitor, and they recognize that perhaps the efficacy isn't there, so we do observe quite a bit of that in the U.S., and second, when you look ahead eight years, we're still identifying new patients in this space, and that's with three major biopharma companies investing in this rare disease, so you do see new patients continuing to come online, and we believe, at least on Biogen's side, we're very effective at patient finding. We can find them fairly quickly. We have an outstanding AI type of tool that we use together with the field force; we're able to locate them at centers of excellence, and physicians can reach out and identify these patients. So with high dose on the horizon, one piece of feedback you hear from physicians and patients is, "We just wish we had more." And with that in mind, we're getting ready right now for that, obviously, the filing and the possible approval moving into label. And we do believe that high dose will also drive growth quarter-over-quarter, year-on-year for at least the U.S. organization.

Steve Amato

executive
#33

Thank you, Alisha. Next question, please, operator.

Paul Matteis

analyst
#34

Hey, I really appreciate you fielding this one. If I try to link a few pieces together, Chris — the people you've brought on board and a few of the calls you've made on older, riskier assets in the portfolio — it seems as though Biogen keeps deepening what it knows in neurology while perhaps also moving its center of gravity somewhere else. Should we be modeling it that way from here on out? Put differently, on the BD side, is there still any willingness on your part to accept neuroscience risk, or is your view that immunology plus rare conditions, where you've built up a lot of know-how over time, will be the place where you win? Thanks.

Chris Viehbacher

executive
#35

The way I'd frame it is that neurology and neuroscience are already a big part of who we are. Obviously we've put very substantial money behind the BIIB080 program, and we keep making a major commitment to Leqembi. We continue to pour hundreds of millions of dollars annually into Leqembi R&D; and behind that, several programs sit in early-stage development; brain shuttle technology is one thing we're advancing, while we also explore other modalities in Alzheimer's. Earlier-stage work in MS and ALS remains underway, plus a sizable Parkinson's effort alongside Denali. So from where I sit, neuroscience is an area where our commitment is already considerable. That said, my own view is that limiting yourself to a single therapeutic area isn't wise. Beyond that, I'd argue our capabilities already stretch past neuroscience. What we call the MS franchise is essentially an immunology franchise — you're addressing MS via the immune system — and I'm convinced we hold a great deal of immunology know-how, which is precisely what made us comfortable pursuing the HI-Bio acquisition. I, and I, I attend plenty of biotech conferences as well as venture conferences. I&I has climbed to become R&D's number two priority, behind oncology; so a great many emerging BD opportunities will show up in that space. Biogen is extremely strong when it comes to small volumes and high-value products, with highly differentiated scientific sell; immunology, I'd say, matches that profile. Rare disease is honestly a commercial label rather than a scientific category. Even so, our rare disease commercial model carries a great deal of capability that plenty of others lack. Growing into that space using that model — being, one could say, indication agnostic — is somewhere we can move. I don't see this as overextending ourselves. Certain capabilities will need to be built. In a sense, Fit for Growth was partly about redirecting emphasis away from the traditional, heavy MS focus and enabling us to take on these other capabilities; but I wouldn't — we truly don't want to enter areas where we'd be competing with really big pharma players on a commercial model. At Biogen, incremental innovation isn't really our game. I'm fairly confident that there are particular immunology spaces where we can broaden our reach — likely ones tied more to uncommon illnesses and neurological disorders within immunology, rather than areas such as RA or atopic dermatitis. Even so, we've got a credible right to compete in those spaces, the wherewithal to do it, and we can genuinely capitalize on the many truly brilliant individuals we have at Biogen.

Steve Amato

executive
#36

Thank you, Chris. We'll move to our last question, please.

Terence Flynn

analyst
#37

Appreciate you fielding this. Mike, I wanted to see if you could walk us through how we should be thinking about margin trajectory for 2025, along with the various tailwinds and headwinds. Thanks.

Mike McDonnell

executive
#38

Absolutely. Terence, let me start by assuming your focus is mainly on the operating income margin; I do believe we've achieved quite solid advancement. The gain during the third quarter came in somewhat below what you had observed. There is some unevenness involved. I'd say that's likely the case, and part of it stemmed from the revenue factors we discussed during the quarter, plus some of the higher-margin products such as Spinraza and Skyclarys. Still, I think viewing it on a year-to-date basis is likely the most useful approach; on the operating income line, we're up 7% year-to-date. To be precise, that's a seven percentage point gain, equating to 23% growth year-on-year; within our guidance, we reference mid-single-digit improvement across the full year and high teens growth across the full year. I believe we're pleased with the advancement we've delivered. We remain confident about securing $1 billion gross and $800 million net in savings, which will keep supporting our margins; we aren't providing guidance past this year. However, as we close out 2024 and move toward 2025, it's worth keeping in mind that regarding the $800 million in savings, we stated we anticipated capturing $400 million by the close of this year, with the remaining $400 million arriving next year. That will keep enhancing our margin profile going forward.

Steve Amato

executive
#39

Mike, thanks. And I appreciate all of you being here with us right now. Naturally, should anything else come up, the IR team is on hand to field those questions. Thanks.

Operator

operator
#40

This concludes today's call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.